Klaria Pharma Holding Quarterly Report Q1 2019

Klaria Pharma Holding Quarterly Report Q1 2019

Encouraging progress in Klaria’s cannabinoid program

First three months of the year (January – March)

Net sales 3,8 MSEK (0,0 MSEK)

R&D costs for the period amounted to 4,8 MSEK (5,1 MSEK)

Net income for the period amounted to -2,1 MSEK (-6,2 MSEK)

Earnings per share amounted to -0,07 SEK (-0,20 SEK)

Cash flow from operations amounted to 0,8 MSEK (-3,7 MSEK)

Cash and cash equivalents on the balance day amounted to 8.7 MSEK (13.4 MSEK)

Shareholder’s equity per March 31, 2019 amounted to 92.6 MSEK (115.8 MSEK)

For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CEO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99 / +46 730-71 64 62

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.